Clinic Roundup

• Ocular Therapeutix Inc., of Bedford, Mass., reported that a Phase II study of sustained-release travoprost (OTX-TP2) for glaucoma and ocular hypertension in 20 patients produced results comparable to topical brand name ophthalmic solutions travatan (Alcon Laboratories), Lumigan (Allergan Inc.) and Xalatan (Pfizer Inc.).